Calypte Biomedical Corp. develops, manufactures and distributes vitro testing products, which improves the diagnosis of Human Immunodeficiency Virus infection, sexually transmitted diseases and other chronic diseases. The company's product line includes both point-of-case rapid tests and traditional ELISA/EIA diagnostic tests. It also offers a broad range of recombinant proteins, antigens, proprietary reagents, buffers, and other specialty products to researchers seeking to develop and optimize immunodiagnostic assays. The company focuses on launching a new line of rapid HIV antibody tests in the United States and other developed nations using a novel lateral flow platform technology and is working to complete development of a nucleic acid-based diagnostic testing platform. Calypte Biomedical was founded in 1988 and is headquartered in Portland, OR.